TrialThe Lancet. Oncology2021

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

Stephen A Boorjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.